A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase II single center, open-label, single arm study in patients with advanced
thymic epithelial tumors after failure of cisplatin-based combination chemotherapy. Patients
will be treated with Pembrolizumab 200 mg every 3 weeks.